It is overexpressed in several cancers and its activity contributes to tumour initiation and growth.12,13 Several studies reported inhibitors of PIN1 but no drug has yet reached the market.14,15 One of the first developed inhibitor, juglone, did not lead to a drug candidate due to the lack of selectivity.16 A large number of phenylimidazole fragments were previously identified as binding to PIN1.17 Here, PIN1 is linked to neoplasm.